Human Papillomavirus in Non-Small-Cell Lung Cancer: The Impact of EGFR Mutations and the Response to Erlotinib

详细信息    查看全文

• 作者：Diego Má ; rquez-Medinap>ap>p> ; p>p>dmarmed@hotmail.comp> ; Ariadna Gasol-Cudó ; sp>ap> ; M. Teresa Taberner-Bonastrep>ap> ; Juan Carlos Samam&#233 ; P&#233 ; rez-Vargasp>ap> ; Antonieta Salud-Salviap>ap> ; Antonio Llombart-Cussacp>bp>
• 关键词：Epidemiology ; Erlotinib ; Human papillomavirus ; Non-small-cell lung cancer ; Epidermal growth factor receptor mutations
• 刊名：Archivos de Bronconeumología (English Edition)
• 出版年：2013
• 出版时间：February, 2013
• 年：2013
• 卷：49
• 期：2
• 页码：79-81
• 全文大小：222 K

文摘

It has been suggested that human papillomavirus (HPV) could participate in the development of non-small-cell lung cancer (NSCLC). A higher HPV infection rate has been reported in the NSCLC samples from Asian non-smoker patients, with adenocarcinomas or responders to EGFR tyrosine kinase inhibitors (EGFR-TKI). We explored a potential relationship between EGFR mutation, response to EGFR-TKI and HPV infection in Western NSCLC patients. We retrospectively analyzed 40 NSCLC samples and the impact of age, gender, histology, tobacco habit and sample type. HPV infection rate was 2.5 % and it was not statistically modified by any analyzed variable, although the limited sample size did not provide definitive conclusions. The rate of HPV infection in NSCLC should be studied in patients with EGFR mutations or a tendency toward presenting them.